Intriguingly, SIRT1 WT complementation facilitated tumor growth and rendered tumors resistant to doxorubicin, whereas SIRT1 KR complementation attenuated tumor growth and sensitized tumors to doxorubicin. This evidence concerns the gene SIRT1 and neoplasm.